Vivalyf Innovations (Easy Life)

Varshitha was born with type 1 diabetes and slipped into a coma on the second day of her life. WEXT India Ventures This extraordinary opening to her life story — a coma at two days old, caused by undiagnosed type 1 diabetes — framed the entire founding motivation for EzLyf. The very first medical crisis of her life was caused by the same condition she would spend her career trying to make more manageable. Varshitha agonised: "Can you imagine getting pricked every day since you were born, wasting 5–6 drops of blood and having to take injections four times a day? It is not only my story, but the story of 537 million people worldwide who suffer from diabetes." Vimal Kumar, the technical co-founder, brings electrical and electronics engineering expertise to the product design. His engineering background is what converts Varshitha's biotechnology research vision into actual hardware: a device with sensors, algorithms, spectroscopic capabilities, and a smartphone interface.

EzLyf (also written as EasyLyf) is India's proposed first non-invasive glucometer — a portable, smartphone-connected device that measures blood glucose levels using spectroscopic technology, without any finger-prick, without any blood, and without any pain. EzLyf offers a painless and affordable solution using spectroscopic technology. It integrates with smartphones, making it user-friendly and accessible. The device is a non-invasive, no-blood, no-pain way to assess the level of glucose in the body for a one-time cost.

Amount Asked: ₹56 lakhs Equity Offered: 7.5% Implied Pre-Money Valuation: ₹7.47 crore

The Vivalyf Innovations pitch was the second of Episode 8 and arrived with one of the most emotionally charged founder introductions of Season 1. Duvvuru Varshitha walking into the Shark Tank as a type 1 diabetic who had slipped into a coma on the second day of her life, and who had cleared IIT but left to pursue a solution to the pain that had defined every day of her existence — this was not a startup pitch. It was a life's purpose on display. across the season. The product demonstration showed the EzLyf device being used: clipped to a finger (a non-invasive process), with the reading transmitted to a smartphone app in real time. No blood. No lancet. No pain. The technology explanation covered the spectroscopic measurement principle, the current accuracy levels (approximately 90%), the government grant already received, the pre-clinical evaluation status, and the regulatory pathway required before commercial launch.

Namita Thapar, as Executive Director of Emcure Pharmaceuticals, brought the most technically informed perspective to the panel. Namita commented that it's going to be a long project, and the chances of success are not that high. Peyush Bansal was the most emotionally connected Shark to the product. Peyush said he can relate personally because his mother is pre-diabetic, and he can relate to the cause. Anupam Mittal joined Peyush's offer, sharing the conviction that the technology was important enough to back even at an early stage. Other Sharks — Ashneer, Aman, and Namita — all exited, each with variations on the same concern: the technology readiness was too early, the accuracy claims needed clinical validation, and the regulatory pathway was long and uncertain.Namita Thapar, as Executive Director of Emcure Pharmaceuticals, brought the most technically informed perspective to the panel. Namita commented that it's going to be a long project, and the chances of success are not that big

The negotiation between Peyush and Anupam's offer and the founders' counter was structured but ultimately irreconcilable on the equity-versus-debt structure. The original ask was ₹56 lakhs for 7.5% equity. Peyush and Anupam offered ₹56 lakhs for a 33.33% stake. Varshitha and Vimal countered with ₹36 lakhs for 15% equity and ₹20 lakhs as debt to be repaid in 3 years Peyush said that repaying the debt would be difficult because the company was currently losing money. Thus he and Anupam kept to their initial offer. The company accepted without hesitation.

Deal Status:- Confirmed & Formally Closed Investment Amount:- ₹56 lakhs Equity Given:- 33.33%